These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 37876726)

  • 41. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
    Burgevin A; Caron B; Sasson A; Luc A; Netter P; Baumann C; Ananthakrishnan AN; Peyrin-Biroulet L
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
    Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
    EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
    Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.
    Holvoet T; Truyens M; De Galan C; Peeters H; Gismero FM; Elorza A; Torres P; Vandermeulen L; Jauregui-Amezaga A; Ferreiro-Iglesias R; Zabana Y; Reverter LP; Geldof J; Lobatón T
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Parrot L; Dong C; Carbonnel F; Meyer A
    Aliment Pharmacol Ther; 2022 Feb; 55(4):380-388. PubMed ID: 34854100
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
    Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
    Attauabi M; Höglund C; Fassov J; Pedersen KB; Hansen HB; Wildt S; Jensen MD; Neumann A; Lind C; Jacobsen HA; Popa AM; Kjeldsen J; Pedersen N; Molazahi A; Haderslev K; Aalykke C; Knudsen T; Cebula W; Munkholm P; Bendtsen F; Seidelin JB; Burisch J
    Scand J Gastroenterol; 2021 Sep; 56(9):1040-1048. PubMed ID: 34224299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort.
    Weaver KN; Gregory M; Syal G; Hoversten P; Hicks SB; Patel D; Christophi G; Beniwal-Patel P; Isaacs KL; Raffals L; Deepak P; Herfarth HH; Barnes EL
    Inflamm Bowel Dis; 2019 Mar; 25(4):767-774. PubMed ID: 30295784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
    Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
    Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
    Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
    Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
    Bressler B
    Therap Adv Gastroenterol; 2023; 16():17562848231159452. PubMed ID: 37057077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
    Gisbert JP; Chaparro M
    Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.